While COVID-19 is an emerging and rapidly evolving situation, the NGCEF members participate in their research works against this pandemic. Please find more details on our publications in the separate menu of our website Covid-19!
Also, this is a Call to all-volunteer scientists for a collective fight against Coronavirus (COVID-19) for the safety of global humanity:
An approach towards the discovery of medicine and vaccine alongside spiritual remedies!
Call for Projects |
|
Herbal drug targets for COVID-19, Type 2 Diabetes, and cancer(s) and possible linkage with each other https://benthamscience.com/journal-files/special-issue-details/CCHTS-SII20201230-01.pdf |
|
Current Overview of implementing phytochemistry and nanotechnology for management of various health issues including COVID-19 https://www.editorialmanager.com/bab/default.aspx, Authors should select VSI: Viral infectious disease |
|
Medicinal Chemistry, "Insights on SARS-COVID-19 and its linkage with cancer using rational drug design: Bioactive compounds using computational approaches", https://benthamscience.com/journal-files/special-issue-details/MC-SII20200622-01.pdf |
|
Linkage of COVID-19 and Neurodegenerative disorders, "CNS & Neurological Disorders - Drug Targets", BMS-CNSNDDT-2020-HT-13 https://bentham.manuscriptpoint.com/submit/Submission/submissionForm/2018/m |
|
Journal: Coronaviruses Current research updates on Coronavirus Outbreak: Overviews of its global impact and consequences https://benthamscience.com/journal-files/special-issue-details/COVID-SII20200714-01.pdf, The thematic issue code is BMS-COVID-2020-HT-1, link for direct submission in the thematic issue: https://bentham.manuscriptpoint.com/submit/Submission/118341/1 |
|
Viral disease and natural products, with a particular focus on COVID-19, Current Pharmaceutical Design (CPD; IF 2.412), BMS-CPD-2020-HT-153 Manuscript submission deadline: 31 July 2020, https://bentham.manuscriptpoint.com/journals/CPD |
| Publications Links |
|
1: Rahman MH, Akter R, Behl T, Chowdhury MAR, Mohammed M, Bulbul IJ, Elshenawy SE, Kamal MA. COVID-19 Outbreak and Emerging Management through Pharmaceutical Therapeutic Strategy. Curr Pharm Des. 2020;26(41):5224-5240. doi: 10.2174/1381612826666200713174140. PMID: 32660401.
2: Ahmed H, Sayed A, Munir M, Elberry MH, Sayed IM, Kamal MA, Negida A, Ebada MA, Bahbah EI. A Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management. Curr Pharm Des. 2020 Dec 22. doi: 10.2174/1381612826666201222162509. Epub ahead of print. PMID: 33355050.
3: Anwar F, Altayb HN, Al-Abbasi FA, Al-Malki AL, Kamal MA, Kumar V. Antiviral effects of probiotic metabolites on COVID-19. J Biomol Struct Dyn. 2020 Jun 9:1-10. doi: 10.1080/07391102.2020.1775123. Epub ahead of print. PMID: 32475223; PMCID: PMC7298884.
4: Anwar F, Naqvi S, Al-Abbasi FA, Neelofar N, Kumar V, Sahoo A, Kamal MA. Targeting COVID-19 in Parkinson's patients: Drugs repurposed. Curr Med Chem. 2020 Sep 3. doi: 10.2174/0929867327666200903115138. Epub ahead of print. PMID: 32881656.
5: Kamal MA, Khan MA. Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part-I). Curr Pharm Des. 2020;26(41):5221-5223. doi: 10.2174/138161282641201126124050. PMID: 33327907.
6: Fatima U, Rizvi SSA, Raina N, Fatima S, Rahman S, Kamal MA, Hassan MI. Therapeutic management of COVID-19 patients: Clinical manifestation and limitations. Curr Pharm Des. 2020 Nov 24. doi:
10.2174/1381612826666201125112719. Epub ahead of print. PMID: 33238869. 7: Alshammary F, Siddiqui AA, Amin J, Ilyas M, Rathore HA, Hassan I, Alam MK, Kamal MA. Prevention Knowledge and Its Practice Towards COVID-19 Among General Population of Saudi Arabia: A Gender-based Perspective. Curr Pharm Des. 2020 Aug 18. doi: 10.2174/1381612826666200818213558. Epub ahead of print. PMID: 32811408.
8: Bhat MA, Rahman S, Rather IA, Banday I, Syed S, Koser H, Kamal MA, Minakshi R, Jan AT. Coronavirus Disease -2019 (COVID-19) in 2020: A Perspective Study of a Global Pandemic. Curr Pharm Des. 2020 Nov 17. doi: 10.2174/1381612826666201118112912. Epub ahead of print. PMID: 33213324.
9: Islam MA, Alam SS, Kundu S, Hossan T, Kamal MA, Cavestro C. Prevalence of Headache in Patients With Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of 14,275 Patients. Front Neurol. 2020 Nov 27;11:562634. doi: 10.3389/fneur.2020.562634. PMID: 33329305; PMCID: PMC7728918.
10: Bibi N, Gul S, Ali J, Kamal MA. Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. Eur J Pharmacol. 2020 Oct 15;885:173496. doi: 10.1016/j.ejphar.2020.173496. Epub 2020 Aug 22. PMID: 32841640; PMCID: PMC7443089.
11: Bibi S, Sarfraz A, Mustafa G, Ahmed Z, Zeb MA, Wang YB, Khan T, Khan MS, Kamal MA, Yu H. The impact of traditional plants and their secondary metabolites in the discovery of COVID-19 treatment. Curr Pharm Des. 2020 Nov 17. doi: 10.2174/1381612826666201118103416. Epub ahead of print. PMID: 33213320.
12: Sohrab SS, Suhail M, Kamal MA, Ahmad F, Azhar EI. The Emergence of Human Pathogenic Coronaviruses: Lectins as Antivirals for SARS-CoV-2. Curr Pharm Des. 2020;26(41):5286-5292. doi: 10.2174/1381612826666200821120409. PMID: 32954998.
13: Wijayasinghe YS, Bhansali P, Viola RE, Kamal MA, Poddar NK. Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19. Curr Pharm Des. 2020 Nov 17. doi: 10.2174/1381612826666201118111151. Epub ahead of print. PMID: 33213322.
14: Batool A, Bibi N, Amin F, Kamal MA. Drug designing against NSP15 of SARS- COV2 via high throughput computational screening and structural dynamics approach. Eur J Pharmacol. 2021 Feb 5;892:173779. doi: 10.1016/j.ejphar.2020.173779. Epub 2020 Dec 1. PMID: 33275961; PMCID: PMC7706467.
15: Bharadwaj S, Azhar EI, Kamal MA, Bajrai LH, Dubey A, Jha K, Yadava U, Kang SG, Dwivedi VD. SARS-CoV-2 M<sup>pro</sup> inhibitors: identification of anti- SARS-CoV-2 M<sup>pro</sup> compounds from FDA approved drugs. J Biomol Struct Dyn. 2020 Nov 5:1-16. doi: 10.1080/07391102.2020.1842807. Epub ahead of print. PMID: 33150855; PMCID: PMC7651494.
16: Satyam R, Jha NK, Kar R, Jha SK, Sharma A, Kumar D, Nand P, Ruokolainen J, Kesari KK, Kamal MA. Deciphering the SSR incidences across viral members of Coronaviridae family. Chem Biol Interact. 2020 Nov 1;331:109226. doi: 10.1016/j.cbi.2020.109226. Epub 2020 Sep 21. PMID: 32971122; PMCID: PMC7505113.
17: Ahmad F, Kamal MA, Tekwani BL. Emergence and Reemergence of Human Coronaviruses: Spike Protein as the Potential Molecular Switch and Pharmaceutical Target. Curr Pharm Des. 2020 Dec 15. doi: 10.2174/1381612826666201216113146. Epub ahead of print. PMID: 33327904.
18: Sohrab SS, Suhail M, Kamal MA, Azhar EI. Natural Products Homoharringtonine and Emetine Alkaloids for SARSCoV-2 Treatment Options. Curr Pharm Des. 2020 Dec 10. doi: 10.2174/1381612826666201210121858. Epub ahead of print. PMID: 33302852.
19: Satyam R, Bhardwaj T, Goel S, Jha NK, Jha SK, Nand P, Ruokolainen J, Kamal MA, Kesari KK. miRNAs in SARS-CoV 2: A Spoke in the Wheel of Pathogenesis. Curr Pharm Des. 2020 Oct 1. doi: 10.2174/1381612826999201001200529. Epub ahead of print. PMID: 33023438.
20: Patel K, Dodds M, Gonçalves A, Kamal MA, Rayner CR, Kirkpatrick CM, Smith PF. Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2. Br J Clin Pharmacol. 2020 Dec 29. doi: 10.1111/bcp.14718. Epub ahead of print. PMID: 33373059.
21: El-Kafrawy SA, El-Daly MM, Hassan AM, Kaki RM, Abuzenadah AM, Kamal MA, Azhar EI. A Direct Method for RT-PCR Detection of SARS-CoV-2 in Clinical Samples. Healthcare (Basel). 2021 Jan 4;9(1):37. doi: 10.3390/healthcare9010037. PMID: 33406585; PMCID: PMC7823392.
22: Kabir MT, Uddin MS, Hossain MF, Abdulhakim JA, Alam MA, Ashraf GM, Bungau SG, Bin-Jumah MN, Abdel-Daim MM, Aleya L. nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics. Front Cell Dev Biol. 2020 Jul 10;8:616. doi: 10.3389/fcell.2020.00616. PMID: 32754599; PMCID: PMC7365855.
23: Dhasmana A, Kashyap VK, Dhasmana S, Kotnala S, Haque S, Ashraf GM, Jaggi M, Yallapu MM, Chauhan SC. Neutralization of SARS-CoV-2 Spike Protein via Natural Compounds: A Multilayered High Throughput Virtual Screening Approach. Curr Pharm Des. 2020;26(41):5300-5309. doi: 10.2174/1381612826999200820162937. PMID: 32867645.
24: Wilkin PJ, Al-Yozbaki M, George A, Gupta GK, Wilson CM. The Undiscovered Potential of Essential Oils for Treating SARS-CoV-2 (COVID-19). Curr Pharm Des. 2020;26(41):5261-5277. doi: 10.2174/1381612826666201015154611. PMID: 33059564. |